Filing Flows › Comparisons › CPHI vs TRDA
China Pharma Holdings vs Entrada Therapeutics: CPHI and TRDA compared
China Pharma Holdings is the larger company: $948K of revenue in its latest quarter (Q2 2026) against $905K for Entrada Therapeutics (Q3 2026). China Pharma Holdings is growing faster (-8% against -44% a year earlier).
Where the money goes: CPHI and TRDA
China Pharma Holdings (CPHI) · Q2 2026
China Pharma Holdings, Q2 2026: revenue $948K (-8% year over year), operating margin -151.0%, net loss $1.5M, operating cash flow −$33K. The chart follows the revenue to costs, profit and cash.
Entrada Therapeutics (TRDA) · Q3 2026
Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year), net loss $39.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
| China Pharma Holdings (CPHI) | Entrada Therapeutics (TRDA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $948K | $905K |
| Revenue growth, Y/Y | -8% | -44% |
| Operating margin | -151.0% | n/m |
| Net earnings | −$1.5M | −$39.7M |
| Net margin | -153.8% | — |
| Operating cash flow | −$33K | −$30.0M |
Questions
Which is bigger, China Pharma Holdings or Entrada Therapeutics?
China Pharma Holdings is the larger company: $948K of revenue in its latest quarter (Q2 2026) against $905K for Entrada Therapeutics (Q3 2026).
Is China Pharma Holdings or Entrada Therapeutics growing faster?
China Pharma Holdings is growing faster (-8% against -44% a year earlier).
More: China Pharma Holdings earnings · how China Pharma Holdings makes money · Entrada Therapeutics earnings · how Entrada Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.